Company intelligence / Profile preview
Aptadel Therapeutics
Barcelona, Catalonia, Spainaptadeltx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Aptadel Therapeutics is a pre-clinical stage biotech developing an RNA aptamer-based platform to deliver various therapeutic agents—including siRNAs, miRNAs, chemotherapeutic drugs, and small molecules—directly into cancer cells. Their lead program targets Ewing Sarcoma using an EphA2-targeting approach. No clinical results have been reported as of May 2025.
- Therapeutic areas
- OncologyHematology
- Modalities
- RNA aptamerssiRNA conjugatesmiRNA conjugatesChemotherapeutic drug conjugatesSmall molecule delivery via aptamer platform
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Spin-off from IDIBELL (Institut d’Investigació Biomèdica de Bellvitge)Co-founded by Fundación Alba
Beyond the preview
Go deeper on Aptadel Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aptadel Therapeutics.